Although clinically less strong than that performed in the US, this study provided the green light to start the procedures necessary to obtain authorization from the European Medicines Agency (EMEA) to use EPO for the treatment of anemia of patients with kidney failure in Europe. The gene discussed is EPO; the disease is kidney failure.